Introduction
Heparanase is the predominant GAG-degrading endoglycosidase that specifically cleaves heparan sulfate (HS) side chains of heparan sulfate glycosaminoglycans -the principal polysaccharide component of the basement membrane and extracellular matrix. Cleavage of HS disintegrates the structural integrity of the basement membrane and releases HS-bound bioactive angiogenic and growth-promoting mediators such as fibroblast growth factor and vascular endothelial growth factor. [1] [2] [3] [4] [5] HS and heparanase have been implicated in diverse processes such as cell proliferation, cell-matrix and cell-cell adhesion, migration, angiogenesis and wound healing. 4, 5 Moreover, HS proteoglycans on the cell surface participate in signal transduction by potentiating the interaction between certain growth factors and their receptors. 4, 5 In addition to localization in the cytoplasm, most likely in lysosomes, heparanase was also noted to assume nuclear localization, demonstrated by cell fractionation and immunostaining of cultured cells and tumor biopsies. [6] [7] [8] [9] Nuclear localization was correlated with cellular differentiation and favorable prognosis of cancer patients, 7, 9 suggesting that heparanase is intimately involved in gene regulation. 8, 9 The heparanase gene (HPSE) is located on chromosome 4q21.3 10 and expressed in a variety of normal cells, among which are cytotrophoblasts, endothelial cells, keratinocytes, mast cells and hematopoietic cells (that is, platelets, neutrophils, macrophages, T and B lymphocytes), mediating their extravasation during inflammatory and immune responses. 11, 12 The heparanase mRNA encodes a 61.2 kDa protein with 543 amino acids. This pro-enzyme is then post-translationally cleaved into 8 (Gln 36 -Glu 109 ) and 50 (Lys 158 -Ile 543 ) kDa subunits that noncovalently associate to form the active heparanase. Heterodimer formation is essential for heparanase activity. 4, 5, 13 Heparanase upregulation was documented in an increasing number of primary human tumors, correlating with enhanced local and distant metastasis, increased microvessel density and reduced postoperative survival of cancer patients. 4, 5 In the hematopoietic system, heparanase is associated with normal differentiation and function of the myeloid lineage. 11 Little or no expression of heparanase was noted in chronic myeloid leukemia (CML) and certain lymphoid malignancies. 11 As the development of malignancy is associated with a loss of normal functions characteristic of mature cells, reduction or loss of heparanase activity may be associated with de-differentiation of hematopoietic cells.
14 However, the possible involvement of heparanase in hematological malignancies was not assessed systematically.
In the present study, we investigated the association between HPSE gene single nucleotide polymorphism (SNPs) and hematological malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), CML, Hodgkin's disease (HD) and multiple myeloma (MM). A statistically significant correlation was found between the HPSE gene SNPs rs11099592 and rs6535455 and ALL (w 2 1d.f. ¼ 4.96, P ¼ 0.026). Genotype frequency comparisons revealed significant associations with SNP rs4693602 (w 2 2d.f. ¼ 7.276, P ¼ 0.026) in MM patients and with SNP rs4364254 (w 2 2d.f. ¼ 6.226, P ¼ 0.044) in AML patients. Examination of HPSE gene mRNA expression by real-time RT-PCR indicated a significant low expression level of the HPSE gene in ALL patients and a high expression level in MM and AML patients, compared to healthy controls. Association analysis between HPSE gene SNPs and heparanase mRNA expression levels among healthy controls revealed a significant association between high levels of heparanase and frequent allele combination (A,G,T) of SNPs rs4693608, rs11099592 and rs4364254, while low heparanase levels correlated with a relatively rare allele composition (G,A,C).
Materials and methods

Patients
Two hundred and fifty-nine consenting patients with hematological malignancies were included in this study among which 80 patients were with AML, 24 with MDS, 43 with ALL, 50 with CML, 44 with MM and 18 with HD. Bone marrow or peripheral blood was collected at diagnosis from the above patients, followed by extraction of DNA and RNA. The marrow and/or blood samples contained about 80-100% blast cells. Since the patient group is heterogeneous, representing various Israeli ethnic populations of different origins, the 103 control healthy individuals were randomly chosen from the same Israeli population. The study was approved by the local IRB and the Israeli Ministry of Health.
SNPs genotyping
The study included six polymorphic SNPs (rs4693608, rs11099592, rs6535455, rs4364254, rs6856901 and rs4693602), which were taken from the NCBI SNPs database (http://www.ncbi.nlm.nih.gov/ projects/SNP/) and the HapMap database (http://www.hapmap. org/index.html.en). These SNPs were mapped in the HPSE gene and were distributed throughout the full gene length (Figure 1) . Some of the SNPs were characterized previously by us in Jewish populations of Israel. 15 Two SNPs (rs4364254, rs4693602) were detected by allele-specific amplification, while the other four SNPs (rs4693608, rs11099592, rs6535455 and rs6856901) were examined by PCR-restriction fragment length polymorphisms (RFLPs)-based assay.
Genomic DNA was prepared from whole blood collected in disodium ethylenediaminetetraacetic acid, applying the Puregene DNA isolation kit (Gentra, Minneapolis, MN, USA). The PCR fragments, which included the six SNPs, were amplified by PCR from genomic DNA, using the forward and reverse primers (Table 1) . PCR amplification was performed as described previously. 15 Temperatures of annealing and PCR product size are summarized in Table 1 . The PCR products were separated by 2% agarose gel electrophoresis and visualized under UV light using ethidium bromide staining. Gels were photographed and analyzed by EDAS 290 Electrophoresis Documentation and Analysis System (Kodak, Rochester, NY, USA).
PCR-RFLPs-based assay
The polymorphic alleles of the rs4693608 SNP were detected using HincII restriction endonuclease (Takara, Shiga, Japan). Following digestion (2 h at 371C), two fragments of 83 and 41 bp were detected when the G allele was included. When the product remained resistant to HincII, the DNA included the A allele.
For determination of rs11099592 polymorphic alleles, the 273 bp PCR product was digested by BstNI restriction endonuclease (New England Biolab, Herts, UK) for 2 h at 601C. BstNI digestion of wild-type DNA (G-allele) yielded fragments of 192, 65 and 16 bp. The G-A substitution led to disappearance of one of the two restriction sites, yielding 257 and 16 bp fragments.
Genotype of the rs6856901 SNP was determined using PflFI restriction endonuclease (New England Biolab, Herts, UK). After digestion (2 h, 371C), two fragments of 278 and 85 bp were detected when the G allele was included. When the PCR product remained resistant to PflFI, the DNA included the C allele.
For detection of the rs6535455 SNP, restriction site of PvuII restriction endonuclease (Takara, Shiga, Japan) was created using primer 5 0 -TGTTTTGTTGCTTTTAAATACAGCT-3 0 . PvuII digestion of wild-type DNA (C-allele) led to appearance of two 
Statistical analysis
Genotype and allele frequencies of the SNPs were calculated by direct counting. Possible differences between samples in the frequency of each of the SNP genotypes or alleles were estimated using the w 2 test, as described. 16, 17 A P-value of p0.05 was regarded as statistically significant. The maximum likelihood (ML) of haplotype frequencies was calculated using the Arlequin software package (http://Lgb.unige.ch/arlequin). 18 
RNA extraction and real-time quantitative RT-PCR
Total RNA was extracted from bone marrow and peripheral blood blast cells using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions and quantified by spectrophotometry. Total RNA (1 mg) was used for a first-strand cDNA synthesis using Reverse Transcription System (Promega, Madison, WI, USA), as described by the manufacturer. SYBR Green (Applied Biosystems, Warrington, UK) real-time PCRs for amplification of heparanase and the house keeping gene L-19 ribosomal RNA were performed using ABI PRISM 7700 sequence detector (Applied Biosystems) in a total volume of 20 ml. The sequences of primers used for detection of the HPSE gene cDNA were 5 0 -GTTCTAATGCTCA GTTGCTCCT-3 0 and 5 0 -ACTGCGACCCATTGATGAAA-3 0 , and for the L-19 ribosomal RNA gene were 5 0 -CTGAAGGTCAAAG GGAATGTG-3 0 and 5 0 -GGACAGAGTCTTGATGATCTC-3 0 . Primer concentration and PCR conditions were optimized. Each cDNA (50 ng) was amplified using 0.5 mM of each primer under the following cycle conditions: 951C for 10 min, followed by 40 cycles of 941C for 15 s and 601C for 1 min. A standard curve was generated for each gene. A dissociation curve was performed after each experiment to confirm that a single product was amplified. The comparative C T method (DDC T ) was used for quantification of the HPSE gene expression and relative quantification (RQ) was calculated as 2
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. The relative heparanase mRNA expression levels among groups of patients with hematological malignancies and healthy controls were evaluated by the Mann-Whitney U-test. t-test was used for evaluation of the association between HPSE gene SNPs and the relative heparanase mRNA expression levels among healthy individuals. P-values of o0.05 were considered statistically significant.
Results
Genetic susceptibility to hematological malignancies
In the present study, 259 patients with different hematological malignancies (AML, MDS, ALL, CML, MM and HD) and 103 normal individuals were genotyped for the HPSE gene SNPs. Exact location of each SNP is noted in Table 1 and Figure 1 . The genotype and allele frequencies of the HPSE gene SNPs are shown in Table 2 . Genotype and allele frequencies of the second SNP (rs11099592) in ALL patients were significantly different from the control group (w Table 3 ). The SNP rs11099592 is A-G substitution, located in exon 8. This alteration results in arginine to lysine replacement at position 307. According to our previous results, 15 rs11099592 was found to be in linkage disequilibrium (LD) only with the rs4693608 SNP in each of the Jewish populations that was studied. However, a significant association was found only with rs11099592. To avoid false-positive results involved in the rs11099592 genotyping, an additional SNP, rs6535455, was genotyped for the ALL patient group and normal controls. This SNP is located in intron 5 at position 8726809 (Acc.no.NT_016354.17), found to be in complete LD with rs11099592, supporting the existence of association between this region of the HPSE gene and the ALL phenotype. In MM patients, the frequency of AA genotype in SNP rs4693602, located in a distal part of the 3 0 -UTR, was three times higher compared to the control group (20.45 and 6.8%, respectively) ( Table 2 ). Statistical comparison of genotype frequency revealed a significant difference between the MM and control groups (w 2 2 ¼ 7.276, P ¼ 0.026) ( Table 3) . In AML patients, the frequency of heterozygotes in SNP rs4364254 was higher (55%) compared to controls (36.9%). Statistical analysis of genotype frequencies revealed significant differences between the AML and control groups (w 2 2 ¼ 6.226, P ¼ 0.044) ( Table 3) .
The genotype frequencies of other SNPs were not significantly deviated from the Hardy-Weinberg distribution (data not shown). Neither were SNPs associated with MDS, HD and CML.
ML estimates of the haplotype (rs4693608, rs11099592, rs4364254, rs6856901 and rs4693602) frequency in ALL patients and controls are presented in Association between HPSE gene SNPs and heparanase mRNA expression levels among healthy individuals Correlation between each SNP and the level of HPSE gene expression was analyzed among 48 normal controls. RQ values of GG (rs4693608) and CC (rs4364254) genotype carriers were significantly lower compared to the other genotype carriers (P ¼ 0.021 and P ¼ 0.027, respectively) ( Table 6 ). The RQ values of healthy individuals with a GG genotype for intermediate SNP rs11099592 were higher in comparison to other controls, although the P-value did not reach significance (P ¼ 0.094).
Next, the influence of allele composition of the first three SNPs (rs4693608, rs11099592 and rs4364254) on HPSE 
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Leukemia expression was examined. While RQ values of normal individuals with frequent allele combination (A,G,T) were higher compared to the other carriers (P ¼ 0.019), low heparanase gene expression levels were associated with rare allele combination (G,A,C) (P ¼ 0.022) ( Table 7) .
Discussion
The most common sequence variation in the human genome is the substitution of a single base, commonly referred to as an SNP. By definition, an SNP is a stable genetic variation in Rare haplotypes of ML frequency less than 5% in both groups are not shown in the table. sequence with a frequency of greater than 1% in at least one population. It has been estimated that the number of SNPs in an individual is in the order of millions, reflecting enormous sequence diversity across all human chromosomes. 20 There is ample evidence to suggest that in common complex trait diseases, genetic factors contribute to the disease process, but it is most likely that multiple genes contribute to disease susceptibility. Although the effect of any single variant is probably small, combinations of SNPs, either as haplotypes, or between distant genes, may coordinately contribute to disease risk. Genetic association studies have emerged as the primary method for studying the effect of SNPs on disease outcome, whether it is susceptibility to a given disease, or differences in phenotypic expression of a known gene. 21 In the present study, 80 AML, 24 MDS, 43 ALL, 50 CML, 44 MM and 18 HD patients, and 103 normal individuals were genotyped for six HPSE gene SNPs (rs4693608, rs11099592, rs6535455, rs4364254, rs6856901 and rs4693602). Analysis of genotype and allele frequencies of these SNPs revealed statistically significant differences between ALL patients and control healthy individuals in rs11099592 and rs6535455 SNPs. Determination of HPSE gene expression levels using real-time PCR showed significantly lower levels of heparanase mRNA in ALL patients compared to controls. Moreover, statistical analysis of genotype frequencies detected a correlation between rs4364254 and AML patients and between rs4693602 and MM patients. Examination of the HPSE gene mRNA levels revealed enhanced heparanase mRNA expression in the two cohorts of patients. The associations found at the genotype level in AML and MM patients may be explained by the existence of specific subgroups among AML and MM patients, in which heparanase may be closely involved in the pathogenesis of the disease. In fact, high levels of active heparanase were found in the plasma and bone marrow of MM patients, associated with increased microvessel density and poor prognosis. 22 Association analysis between heparanase mRNA expression levels and HPSE gene SNPs among healthy controls revealed an association between frequent allele composition (A,G,T) and The Mann-Whitney U-test was employed and Pp0.05 was considered significant. RQ values of ALL patients were significantly lower, P ¼ 0.0001, than those of normal controls. Expression levels of heparanase among AML and MM patients were significantly higher compared to controls (P ¼ 0.003 and 0.04, respectively). ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; MM, multiple myeloma. high expression level of heparanase. On the other hand, low heparanase mRNA expression levels correlated with rare allele composition (G,A,C). These results suggest the presence of certain regulatory elements in the three SNPs block area that may affect basal HPSE expression and contribute to predisposition of malignant and inflammatory disorders in which heparanase is involved. Further genetic studies in a large cohort of healthy individuals with known haplotypes will enable to better elucidate the role of specific SNPs in the control of HPSE gene expression. SNP rs11099592 is an A-G replacement, located in the coding region of the HPSE gene (exon 8) resulting in substitution of arginine to lysine at position 307. Since arginine and lysine are basic amino acids, it is not obvious whether this type of modification may result in heparanase functional distortion. There are examples, however, that even wobble polymorphisms are associated with a change in mRNA and protein expression levels. 23 Another SNP (rs4693602) in the HPSE gene found to be associated with MM is mapped to a distal part of the 3 0 -UTR. 3 0 -UTR is an important regulatory region of genes and hence this polymorphism may modify the expression of the HPSE gene. 24 The fact that different regions of the HPSE gene were found to be associated with various hematological malignancies may indicate the presence of distinct genetic or epigenetic alterations in the HPSE gene. Moreover, the expression levels of the HPSE gene were lower in ALL and higher in MM and AML patients, in comparison to normal controls. Thus, the putative role of the HPSE gene in the pathogenesis of hematological malignancies may be disease specific.
Acute leukemia is a heterogeneous disease with numerous genetic abnormalities that define each subtype. Many of the known chromosomal translocations and mutations in leukemia target genes and pathways disrupt hematopoietic transcription factors and/or confer a proliferative and survival advantage to leukemic blasts. 25 ALL is a heterogeneous group of lymphoid malignancies that result from clonal proliferation and expansion of immature lymphoid cells in the bone marrow, blood and other organs. 26 In most patients, the cause of ALL is unknown. A higher incidence of ALL has been noted among monozygotic and dizygotic twins of ALL patients, reflecting possible genetic predisposition. Moreover, patients with trisomy 21, Klinefelter's syndrome, Fanconi anemia, Bloom syndrome and ataxiatelangiectasia have a higher risk of developing ALL. 26 Recent data have indicated that in pediatric leukemia, most chromosome translocations and preleukemic clones arise during fetal hematopoiesis with secondary genetic events. 25 AML is infrequent, yet it is a highly malignant neoplasm responsible for a large number of cancer-related deaths. Known risk factors include age, antecedent hematological disease, previous chemotherapy and genetic disorders. 27 In any event, leukomogenesis of ALL and AML is a multistep process that requires the susceptibility of hematopoietic progenitor cells to inductive agents at multiple stages. 26, 27 Our findings suggest that genetic alterations in the HPSE gene may be involved in certain stages of ALL and/or AML leukomogenesis.
Previous studies 11, 14 indicated that heparanase plays a role in the normal function of hematopoietic cells. Presumably, heparanase may be involved in differentiation of hematopoietic cells by releasing HS-bound bioactive mediators (that is, cytokines, chemokines), which may, among other effects, regulate gene expression. 5, 28 Reduction or loss of heparanase activity may be associated with de-differentiation of leukemic cells.
14 Whether gene transcription and maintained cellular differentiation is due to direct interaction of heparanase with the DNA, or is a consequence of heparanase-mediated degradation of nuclear HS, is yet to be demonstrated. 8, 9 MM is a B-lymphoid malignancy characterized by tumor cell infiltration of the bone marrow, osteolytic lesions and angiogenesis in the vicinity of the tumor cells. A subpopulation of myeloma cells within the human bone marrow expresses high levels of heparanase. 22 Heparanase enzymatic activity was detected in the bone marrow and plasma of the majority of myeloma patients, although the levels of activity varied among patients. 22 Moreover, high heparanase activity in myeloma correlated with high microvessel density and with altered HPSE expression that may promote an aggressive tumor phenotype. 22 Our results corroborate these observations, indicating a major role of heparanase in MM. Further studies will enable to clarify better the function of HPSE in MM and elucidate the contribution of the HPSE SNP rs4693602 to disease progression.
The current study provides, for the first time, characterization of HPSE gene SNPs in various hematological malignancies and reveals associations between the HPSE and the development of ALL, and to a lesser extent AML and MM. This information may assist further genetic and genomic studies, which will enable to better elucidate the importance and clinical significance of the HPSE gene in hematological neoplasms.
